Rebastric Medisun treatment for stomach ulcer, duodenum (10 blisters x 10 tablets)

Dosage form Box of 10 blisters x 10 tablets
Specifications Rebamipide

Ingredient

Composition information	Content
Rebamipide	100mg

Uses

indications

Rebastric medicine is indicated in the following cases:

Treatment of gastric ulcer. In mice, including ulcers created by stress, when soaked in water, due to aspirin, indomethacin, histamine, serotonin and pyloric gasters.

The drug also protects the mucosa from damage due to other conditions that cause an ulcerative that generates the reaction of oxygen roots, including blood supply for ischemic mucosa, using platelet activation factors (PAF) or Diethyldithocarbamate (DDC) and using indomethacin in stress.

Preventive or healing effects in gastritis: Rebamipide prevents the development of taurocholic acid (one of the main ingredients of bile acid) –The inflammation of the mucosa and promotes the healing of gastric mucosa.

The effect of increasing prostaglandin: Rebamipide increases the formation of prostaglandin E2 (PGE2) in the gastric mucosa in the mouse. The drug also increases the content of PGE2, 15-keto-13, 14-dihydro-Pge2 (is a metabolic substance of PGE2) and Prostaglandin I2 (PGI2) in gastric juice.

Protect gastric cells: Rebamipide shows the effect of protecting stomach cells, inhibiting mucosal damage caused by ethanol, strong acids or strong base, and the drug also protects stomach epithelial cells.

The effect of increasing mucus: Rebamipide promotes the activity of the gastric enzyme to synthesize glycoprotein with high molecular weight, thicken the mucus layer on the surface of the stomach lining and increase the amount of mucus soluble in the stomach.

The effect of increasing blood flow into the mucosa: Rebamipide increases blood flow into the stomach lining and improves hemodynamic hemodynamics decreased after blood loss.

Effects on the mucosal fence: Rebamipide usually does not affect the difference possible about transmission through the stomach lining.

Effects on the stomach secretion: Rebamipide promotes the secretion of the stomach.

Effects on the number of mucosal cells: Rebamipide activates the proliferation of the stomach lining and increases the number of epithelial cells.

Effects on the restoration of gastric mucosa: Rebamipide recovers slowly healing of artificial wounds caused by bile acid or hydrogen peroxide in gastric epithelial cells.

Effects on the secretion of the stomach: Rebamipide does not change the alkaline secretion of the gastric juice or the acid secretion is stimulated by the secretions.

Effects on oxygen roots: Rebamipide type Hydroxyl radicals directly and prevent the production of superoxide due to granulocytes. The drug prevents the damage to the stomach lining cells caused by the reaction of oxygen radicals released from neutrophils stimulated by Helicobacter pylori in vitro.

Effects on inflammatory cell infections in the gastric mucosa: Rebamipide prevents inflammatory cell infections in the mouse -generated gastritis caused by taurocholic acid (one of the main ingredients of bile acid) and lesions of the gastric mucosa created by nonsteroidal anti -inflammatory drugs (NSAIDs) or due to blood supply in local anemia.

Effects on cytokine release (Interleukin-8) causing inflammation in the gastric mucosa: Rebamipide, oral use, preventing Interleukin-8 production in the stomach lining of patients infected with Helicobacter pylori. The drug also inhibits the activation of the kappa-B factor of the nucleus, the appearance of Interleukin-8 MRNA and the production of Interleukin-8 in the epithelial cell cultured with Helicobacter pylori.

Dynamic pharmacokinetics

Absorption: After taking single dose 100 mg Rebamipide: Tmax = 2.4 hours, cmax = 216 mcg/l; The speed of rebamipide absorption is slow when the drug is taken orally at a dose of 150 mg for 6 healthy people after a meal compared to the absorption rate if taken before eating. However, food does not affect the bioavailability of the drug in humans.

Distribution: Rebamipide at the dose of 0.05–5 mcg/ml is put into Vitro -in -Vitro plasma. 98.4–98.6% of the drug associated with plasma protein.

Metabolism: A metabolite has a group of hydroxyl in the 8th place found in urine. However, this metabolic excretion is only about 0.03% of the dose used. The enzyme related to the formation of this metabolite is Cytochrome P450 3A4 (CYP3A4).

Elimination: Mainly excreted in urine in the form of constant drugs. When healthy men use a single dose of Rebamipide 100 mg, about 10% of the doses have been deducted from urine. The sale time of the drug is 1.9 hours.

Before taking Rebastric Medisun treatment for stomach ulcer, duodenum (10 blisters x 10 tablets)

How to use

Rebastric medicine used oral. Take medicine in the morning, evening and before going to bed.

Dosage

Dosage to treat stomach ulcers: The common dose for adults is 100 mg x 3 times/day.

Dosage to treat gastric mucosa lesions: The dose commonly used for adults is 100 mg x 3 times/day.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

No report on overdose.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Rebastric medicine, you may experience unwanted effects (ADR).

Rare, 1/10000

leukopenia.

Liver dysfunction.

Not determined frequency

Shock and anaphylactic reaction.

platelet reduction. jaundice.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

contraindicated Rebastric medicine in the following cases:

Hypersensitivity to one of the ingredients of the drug.

Be cautious when using

should eliminate the possibility of patients with malignant tumors before treatment.

Severe liver disease.

Pregnant women.

Do not use during breastfeeding.

Lightweight babies, newborn babies, breastfed and children: Safety has not been fully considered.

Elderly patients to minimize the risk of stomach - intestinal disorders.

The ability to drive and operate machinery

has recorded a number of patients with dizziness or drowsiness while using Rebamipide 100 mg. Should be cautious when driving and operating machinery.

Pregnancy

Rebamipide should only be used for pregnant women if the benefit of the estimated treatment is considered to be higher than any risk that may be (unknownly the safety of this drug in pregnant women).

Breastfeeding period

Women who are breastfeeding must stop using Rebamipide.

Drug interaction

increases the concentration of diazepam, phenytoin, and warfarin in plasma.

Storage

In a dry place, temperatures below 30ºC.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.